Gilead’s hep C drugs make it king of the hill in U.S. drug sales

By 

The U.S. drug market is the largest in the world and just about every drugmaker wants the biggest piece of it that it can get. For 2014 that honour goes to biotech Gilead Sciences ($GILD), whose hep C drugs vaulted it to the top, according toPMLiVE based on sales info from GlobalData. Sovaldi and Harvoni helped it reach total U.S. sales of $17.975 billion in 2014, the data showed, topping the $17.432 billion that Johnson & Johnson ($JNJ) turned in. Pfizer ($PFE), which PMLiVEsays topped the list for 10 years, fell to third place as its U.S. sales shrank by 7% last year in the face of generic competition for Lipitor and other drugs. Roche ($RHHBY) at $16.643 billion and Novartis ($NVS) at $15.185 billion rounded out the top 5 in U.S. sales for the year.

http://www.fiercepharma.com/story/gileads-hep-c-drugs-make-it-king-hill-us-drug-sales/2015-04-15

 

Leave a Reply